The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO GI 2021 | Real-world safety of second-line 5-FU regimens in mPDAC

Name: Real-world safety of second-line 5-FU regimens in mPDAC
Uploaded: 2021-01-15T00:00:00Z
Duration: 33 s
Description: Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, outlines the real-world safety data and differentiation of second-line 5-FU based regimens in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Zev Wainberg • 15 Jan 2021

ASCO GI 2021

Gastrointestinal Cancer Pancreatic Cancer 5-fluorouracil

Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, outlines the real-world safety data and differentiation of second-line 5-FU based regimens in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).